Sign in

Maya Eskandarani

Senior Equity Research Analyst at H.C. Wainwright & Co.

Maya Eskandarani is a Senior Equity Research Analyst at H.C. Wainwright & Co., specializing in biotechnology and healthcare sectors. She provides coverage on emerging companies such as MAIA Biotechnology, and is recognized for issuing timely Buy and Hold ratings, with her calls contributing to multi-month stock price targets and notably positive analyst sentiment in recent periods. Eskandarani began her career in life sciences research before transitioning to equity analysis, joining H.C. Wainwright in the early 2020s after earning her advanced degree in biological sciences. She holds FINRA Series 7 and 63 licenses and is registered as a securities professional, continually cited for her in-depth expertise in oncology therapeutics and early-stage biopharma.

Maya Eskandarani's questions to MediWound (MDWD) leadership

Maya Eskandarani's questions to MediWound (MDWD) leadership • Q2 2025

Question

In a follow-up, Maya Eskandarani of H.C. Wainwright & Co. asked about the risk of FDA inspection delays for the new facility and whether the BARDA RFP and DoD funding for a room-temperature stable NexoBrid formulation overlap.

Answer

CEO Ofer Gonen stated he does not foresee issues with the FDA inspection timeline, as it's expected in late 2026, and noted that revenue guidance is primarily dependent on the EMA approval, which faces no such delays. He confirmed that both BARDA and the DoD are interested in the room-temperature stable formulation, highlighting its dual military and civilian applications.

Ask Fintool Equity Research AI